PASI 75 isn't clearance, and not all patients are hitting that goal.
1. The results are spectacular, but there's room for improvement, even in most of the patients who respond,
2. There are obviously patients who do not respond as dramatically, and
3. MEDI-507 is believed to eliminate the effector cell, hopefully through apoptosis. To neutralize TNF is to neutralize a product of the effector cell.
So, two thoughts...... there's lots of room for a second, effective molecule, and there's every reason to believe that either the BGEN or MEDI/BTRN approach is just plain better. Enbrel (I wouldn't worry about Remicade) is going to start stealing market share from day one, and will be tough to displace. But, as Miljenko pointed to, we've known that. Maybe the market learns it anew on occasion (like yesterday), but these facts have been on the table for some time.
I'm no more worried about Enbrel than I have been for some time. No change, IMO....... plenty of room for another company to command market share.
That said, I hold only a modest position...... anyone who reads the thread will see how ticked I was about the Eligix move (I am still a supporter of Elliot L., however), and MEDI has been a terrible/blind/almost inept partner IMO. |
